Amgen Lifts Full-Year Outlook After Q2 Sales Smash Estimates
AMGN sits 44% above its 52-week low of $269.77.
Summary
Amgen raised its full-year profit and revenue guidance after Q2 sales of key medicines beat expectations. The company reported adjusted EPS of $6.29 versus the $5.62 consensus and revenue of $10.1B, driven by stronger-than-expected product sales. This follows a turbulent period marked by the proposed U.S. withdrawal of Tavneos and a recent cybersecurity breach, making the raised outlook a notable positive signal. The guidance hike suggests management sees sustained momentum despite recent headwinds.
At the time of this announcement, AMGN was trading at $389.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.5B. The 52-week trading range was $269.77 to $398.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Binance News.